Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine for Oxygen Dependent Meconium Aspiration Syndrome
NCT06972108Phase 2Not yet recruiting
- Sponsor
- University of Alberta
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial in Meconium aspiration syndrome (MAS) comparing Caffeine arm with Placebo arm (2 arms). Primary endpoints: 24 hours oxygenation- 48-72 hours and 24 hours oxygenation - 72 hours. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
caffeine
03
Conditions
Meconium aspiration syndrome (MAS)
Beyond the preview
Go deeper on NCT06972108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972108.